MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1161/hypertensionaha.126.27431

Медицинская библиотека · Hypertension (Dallas, Tex. : 1979) · 2026

Primary Aldosteronism Medical Treatment Outcomes (PAMO) Beyond 12 Months.

Yang Jun, Goi Jessica, Burrello Jacopo, Reincke Martin, Adolf Christian, Brüdgam Denise, Li Qifu, Song Ying, Hu Jinbo, Yang Shumin, Satoh Fumitoshi, Ono Yoshikiyo, Libianto Renata, Stowasser Michael, Li Nanfang, Zhu Qing, Hong Namki, Nayak Drishya, Puar Troy H, Wu Vin-Cent, Vaidya Anand, Araujo-Castro Marta, Kocjan Tomaz, O'Toole Samuel Matthew, Hundemer Gregory L, Ragnarsson Oskar, Lacroix André, Larose Stephanie, Nakai Kazuki, Nishikawa Tetsuo, Ladygina Daria, Turcu Adina F, Vibhatavata Peeradon, Fardella Carlos E, Uslar Thomas, Quinkler Marcus, Mulatero Paolo, Pintus Giovanni, Rossi Gian Paolo, Hahner Stefanie, Amar Laurence, Drake William M, Varsani Chetna, Brown Morris J, Wu Xilin, Young William F, Williams Tracy Ann, Fuller Peter J

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Primary aldosteronism (PA) is a common and treatable cause of hypertension, yet data on the durability of medical treatment response beyond the first year are limited. Using the PA medical treatment outcomes framework, we evaluated long-term biochemical and clinical outcomes and factors associated with treatment response.

METHODS

We conducted an international, multicenter, observational cohort study across 27 centers on 4 continents. Adults with PA treated with mineralocorticoid receptor antagonists and/or epithelial sodium channel blockers between 2016 and 2021 were included if follow-up data were available at ≥12 months. Biochemical and clinical responses were classified as complete, partial, or absent using PA medical treatment outcomes criteria. Ordinal logistic regression identified determinants of a favorable treatment response.

RESULTS

The cohort included 1292 patients (47.5% women, mean age 52 years) with a median follow-up of 34 months (interquartile range, 21-51). At ≥12 months, 58.3% achieved a complete biochemical response, and 20.8% achieved a complete clinical response, with only 5% showing no response. Determinants of a favorable biochemical response included lower aldosterone and lateralization index, and higher renin and potassium levels at baseline. In those taking spironolactone, a higher daily dose was also associated with a favorable biochemical response. Determinants of a favorable clinical response included female sex, lower body mass index, shorter duration of hypertension, and absence of hypertension-mediated organ damage.

CONCLUSIONS

Targeted medical therapy for PA can deliver sustained biochemical and clinical benefits. Early disease detection and adequate dose titration are highly actionable determinants of long-term treatment success.

Для цитирования: Yang Jun, Goi Jessica, Burrello Jacopo, Reincke Martin, Adolf Christian, Brüdgam Denise, Li Qifu, Song Ying, Hu Jinbo, Yang Shumin, Satoh Fumitoshi, Ono Yoshikiyo, Libianto Renata, Stowasser Michael, Li Nanfang, Zhu Qing, Hong Namki, Nayak Drishya, Puar Troy H, Wu Vin-Cent, Vaidya Anand, Araujo-Castro Marta, Kocjan Tomaz, O'Toole Samuel Matthew, Hundemer Gregory L, Ragnarsson Oskar, Lacroix André, Larose Stephanie, Nakai Kazuki, Nishikawa Tetsuo, Ladygina Daria, Turcu Adina F, Vibhatavata Peeradon, Fardella Carlos E, Uslar Thomas, Quinkler Marcus, Mulatero Paolo, Pintus Giovanni, Rossi Gian Paolo, Hahner Stefanie, Amar Laurence, Drake William M, Varsani Chetna, Brown Morris J, Wu Xilin, Young William F, Williams Tracy Ann, Fuller Peter J. Primary Aldosteronism Medical Treatment Outcomes (PAMO) Beyond 12 Months.. Hypertension (Dallas, Tex. : 1979). 2026. DOI: 10.1161/hypertensionaha.126.27431.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.